On this page · 5 sections→
Where the EU money came from
Funding by EU programme. Amounts are Tes Pharma SRL's own share of each project, not the project's full budget.
- FP7 (2007 to 2013)€383k · 1 project
- Horizon 2020€0 · 1 project
Projects
2 EU-funded projects, newest first. Each links to the official record.
- TREAT-NPM1-AMLAssociated partner
Improving therapy of NPM1-mutated AML
Horizon 2020 · 2017–2022 · Project on CORDIS ↗
- FXR-IBDPartner
Industry-Academia exchange to further FXR-based therapeutic intervention and non-invasive diagnosis in Inflammatory Bowel Disease
FP7 (2007 to 2013) · 2014–2018 · Project on CORDIS ↗
€383ktheir share
Works most with
Organisations that shared the most EU projects with this one. A good starting list for consortium partners.
Fields it works in
Research fields recorded on its Horizon projects.
- inflammatory bowel disease
- leukemia
- microbiology
- molecular biology
- mutation
- pharmacology and pharmacy
- proteins
- stem cells
- transplantation
Is this your organisation?
Claim it with an EUACC listing (€39 once, reviewed by our editors): add what you build, your team and what you are looking for. We pre-fill it from your EU records. Listed companies reach investors through our newsletter and get matched to new EU calls first.
Claim this profile →Source: CORDIS (Horizon Europe, Horizon 2020, FP7) and the EU Funding & Tenders Portal (other EU programmes), matched by the EU registration number (PIC). Past participation does not mean the organisation is open to new partnerships. Official website ↗